Clinical Trial Update: An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

View source ↗

Summary

Completed clinical trial evaluating Fluorodopa F-18 PET/MRI to assess treatment response in high-grade soft tissue sarcoma, highlighting imaging utility for res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Fluorodopa F-18 (18F-fluorodopa)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma | Status: COMPLETED